Author Affiliation: Department of Surgery, Section of Cardiothoracic Surgery, Temple University School of Medicine, Philadelphia, Pennsylvania.
The introduction of the LAS significantly changed the face of LTx,1 but the question remains, has the change been for the better or for the worse? Instead of accruing time on the waiting list, the LAS seeks to identify those most likely to benefit by taking the difference between factors associated with 1-year posttransplant survival and the likelihood of dying while on the waiting list. The fact remains that fewer than 50% of all LTx recipients are alive at 5 years, which begs the question as to whether posttransplant survival should be given increased weight in the LAS calculation.
Kaiser LR. Donor Lung Allocation: Comment on “Lung Transplant in Idiopathic Pulmonary Fibrosis”. Arch Surg. 2011;146(10):1209–1210. doi:https://doi.org/10.1001/archsurg.2011.242
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: